Biotech
Commented by Carsten Mainitz on June 8th, 2022 | 11:35 CEST
Valneva, Defence Therapeutics, Bayer - Blockbusters: Turbos for your share portfolio!
Blockbusters are drugs with which companies generate sales of more than USD 1 billion per year. Corona vaccines are currently an integral part of the global hit list. But also many application areas in different cancer fields or cardiovascular diseases offer a large market worth billions. Like BioNTech, a company with the right pipeline and the resulting compounds can quickly evolve from a start-up into an established and profitable player.
Read
Commented by Carsten Mainitz on June 7th, 2022 | 11:32 CEST
XPhyto, BioNTech, MorphoSys - The next price wave is coming!
In recent years, Corona has been the most urgent topic that has moved the world and the stock markets. Health care is and remains a megatrend. It is in the nature of things that the focus changes over time. Innovative approaches or forms of drug delivery, on the other hand, remain perennial favorites. There is also a lot of progress in research against cancer. These companies will play a major role in the future.
Read
Commented by Stefan Feulner on June 1st, 2022 | 14:03 CEST
After the slump in biotech stocks - Bavarian Nordic, XPhyto and Evotec under review
Biotechnology experienced a boom in March 2020, when the world realized what biotech innovations could do to fight COVID-19. Investors pounced on the many promising technologies, driving up the stock prices of vaccine producers and making it easier for companies to raise capital for financing. However, since September of last year, the biotech sector has been on a steep downhill slide, at least on the stock market. The NASDAQ Biotechnology Index has lost more than 30% of its value since its high of 5,449.26 points until today. This drastic decline is reminiscent of the bursting of the bubble in the year 2000. But where are the opportunities now, and which stocks should investors rather refrain from investing in?
Read
Commented by Fabian Lorenz on June 1st, 2022 | 13:44 CEST
Rain of money for BioNTech shareholders: What are Nordex and Meta Materials doing?
BioNTech shareholders are in for a windfall. A dividend of EUR 2 per share is to be approved at today's Annual General Meeting. Also on the agenda is a share buyback program with a volume of up to USD 1.5 billion. In addition, analysts at Goldman Sachs have commented positively on the German biotech champion. Meta Materials shareholders are still a long way from a dividend. But the hot stock has announced exciting details about its fight against stroke. At Nordex, by contrast, supply chain problems, plant closures and cyberattacks dominate the headlines. But analysts see the light at the end of the tunnel - and rightly so?
Read
Commented by André Will-Laudien on May 31st, 2022 | 12:03 CEST
Watch out: BioNTech, NervGen, MorphoSys, Valneva: Biotech shares in check!
The initial sell-off in biotech stocks seems to have been digested. With last week's NASDAQ turn, spring air is now moving through the stock markets again. That is because many investors realize that, in the face of a multitude of new diseases, a major research effort is needed to protect humanity from the burgeoning dangers. Financing via the stock market was correspondingly easy for the biotech giants during the last pandemic because investors sensed big profits in the event of success. This picture is likely to repeat itself in the next movement. Where are the current opportunities in the biopharma sector?
Read
Commented by Juliane Zielonka on May 27th, 2022 | 12:39 CEST
BioNTech, XPhyto Therapeutics, Snap Inc. - Tech falls, biotech gains
The bearish market continues to slide. Tech companies like Snap Inc. saw share price declines of 31%. An alternative to high growth stocks are life science accelerators like XPhyto Therapeutics Corp. They are betting on the right partners and funds to bring biotech products to market faster than usual. While still with emergency approval, BioNTech is at the starting line for a Corona vaccine. Both German STIKO and partner Pfizer in the US are now targeting children for a COVID-19 vaccine.
Read
Commented by Stefan Feulner on May 23rd, 2022 | 13:01 CEST
BioNTech, Monkeypox, Defence Therapeutics, Valneva - Is the next threat coming after Corona?
The Corona pandemic is not over yet, but we should already prepare for future viruses. The next pandemic will come. When it will come is uncertain, and so is which pathogen will we have to deal with. Monkeypox is now spreading globally, and there are already the first cases in Germany. We find out what is known so far, where the dangers lie and what opportunities there are for the biotechnology sector from Dr Moutih Rafei, a renowned pharmacologist and head of research and development at the innovative company Defence Therapeutics Inc.
Read
Commented by Fabian Lorenz on May 19th, 2022 | 13:31 CEST
Booster for the BioNTech share: BASF and Defense Metals with momentum?
The swing market continues to keep investors on their toes. On Tuesday, encouraging economic data and the prospect of an imminent end to the lockdowns in China ensured a good mood and significantly rising prices. The speech by Fed Chairman Powell could not change this. Only one day later, the euphoria has already faded, and the statements of the central bank chief are being interpreted negatively. Powell had reiterated the Fed's determination to fight inflation. Therefore, operational impulses are needed for shares to rise again. BioNTech's stock got a small boost from the FDA's approval of its Corona vaccine as a booster shot for ages 5-11. But analysts are waiting for more. At Defense Metals, investors hope for more from today's CEO presentation after solid drilling results. At BASF, several analysts are reducing price targets at once and see possible additional costs in the billions.
Read
Commented by Juliane Zielonka on May 19th, 2022 | 11:14 CEST
Amazon, Edgemont Gold, Valneva - The real gold wins
Only 'cash is king' seems to be the motto of this stock market week. High inflation is bringing tech stocks to their knees, and heavy artillery is also being brought to bear on Valneva's dead vaccine development front. The EU Commission wants to cancel the preliminary contract if the vaccine is not finally delivered within a month. Depth is also to be expected at Edgemont Gold, only this time, good things are hidden there. The gold exploration company is getting promising results from its third drill hole.
Read
Commented by Nico Popp on May 18th, 2022 | 12:53 CEST
Big percentages thanks to platform strategy: Amazon.com, Defence Therapeutics, Nordex
A central principle of the platform economy is to bring together different user groups and thus create synergies. What sounds a bit dry quickly becomes interesting, especially from an investor's point of view. For example, when different car models are based on one and the same platform, or when several diseases can be effectively combated thanks to one and the same technology. The unique aspect for investors: If these synergies come to fruition and a business succeeds in scaling, high returns are possible. We cite three stocks as examples.
Read